Table of Contents
✨ Onyx Summary
Recursion Pharmaceuticals announced participation in two upcoming investor conferences: the Citi 2025 BioPharma Back to School Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025.
The company’s engagement underscores its strategy to highlight progress in scaling its Recursion OS platform, which integrates machine learning, high-throughput experimentation, and massive datasets to drive drug discovery and development.
Salt Lake City,Aug. 27, 2025 – Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
- Citi 2025 BioPharma Back to School Conference —Wednesday, September 3, 2025
- Morgan Stanley 23rd Annual Global Healthcare Conference —Monday, September 8, 2025
Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area.
Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Investor Contact
investor@recursion.com
Media Contact
media@recursion.com
